Abstract: The present disclosure relates methods for treating skin disorders caused by an immune deficiency with topical formulations comprising ethyl (R)-4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (Compound I) or pharmaceutically acceptable derivative thereof. In particular, the topical formulations described herein may be used to treat atopic dermatitis, alopecia areata, or vitiligo.

Abstract: Compositions and methods that may be useful for the treatment of a viral infection as well as for treating infection induced cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) are described herein. For example, pharmaceutical compositions containing Compound I as disclosed herein may be used to treat infection by a coronavirus, such as SARS-CoV-2 (“COVID-19”).

Abstract: Methods of treating vitiligo using JAK/STAT modulating compounds are provided herein. The JAK/STAT modulating compounds may be selected from 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methylpyrimidin-4-yl)amino)benzo[d] oxazol-2(3H)-one, disodium (5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methylpyrimidin-4-yl)amino)-2-oxobenzo[d]oxazol-3(2H)-yl)methyl phosphate, tofacitinib, ruxolitinib, baricitinib, lestaurtinib, decernotinib, TG101348, Janex 1, PF-956980, WHI-P154, ZM-39923, NSC114792, cerdulatinib, fedratinib, PF-06263276, CEP-33779, AZD-1480, SHR0302, oclacitinib, filgotinib, gandotinib, momelotinib, pacritinib, upadacitinib, peficitinib, PF-04965842, N-(3-acetamido-5-(quinaxalin-2-yl) phenyl) acrylamide, 1-[(2S,5R)-2-Methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one malonate (PF-06651600), [(1S)-2,2-Difluorocyclopropyl][3-[2-[(1-methyl-1H-pyrazol-4-yl)amino]-4-pyrimidinyl]-3,8-diazabicyclo[3.2.